We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




HLF-Gene Controls Generation of Immune System

By LabMedica International staff writers
Posted on 06 Dec 2017
Blood stem cells give rise to all of the blood cells, the red blood cells that transport oxygen, the platelets that enable blood coagulation, and our immune cells that protect us from infections.

Immune cells can, in turn, be divided into two groups; one that consists of cells with a very short life expectancy and a natural but rather unspecific ability to counteract infections (myeloid cells), and another that, in contrast, consists of very long-lived cells (lymphocytes) that specialize in combatting specific bacteria and viruses.

An international team of scientists collaborating with Lund University (Lund, Sweden) personnel identified robust expression of the leukemia-associated transcription factor hepatic leukemia factor (Hlf) in normal multipotent hematopoietic progenitors, which was rapidly downregulated upon differentiation. More...
Interference with its normal downregulation revealed Hlf as a strong negative regulator of lymphoid development, while remaining compatible with myeloid fates.

They also observed rapid lymphoid commitment upon reduced Hlf activity. The arising phenotypes resulted from Hlf binding to active enhancers of myeloid-competent cells, transcriptional induction of myeloid, and ablation of lymphoid gene programs, with Hlf induction of nuclear factor I C (Nfic) as a functionally relevant target gene. Patients with leukemia in which the HLF gene is involved have a very poor prognosis, but it has been difficult to generate reliable models for studying the emergence, development and possible treatment of these leukemias more thoroughly.

David Bryder, PhD, a professor and lead investigator of the study, said, “Our studies revealed that if the immature blood cells are unable to shut down the HLF gene at the correct stage of development, the lymphocytes, the long-lived immune cells, are unable to form. As a result, you will only have one type of immune defense. An increased understanding of these processes is crucial as immune cells in patients who undergo bone marrow transplants are regenerated very slowly, which results in a long period of immune sensitivity.” The study was published on November 21, 2017, in the journal Cell Reports.

Related Links:
Lund University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Repetitive Pipette
VWR® Stepper Pro
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.